User menu

Antacid-induced osteomalacia.

Bibliographic reference Boutsen, Yves ; Devogelaer, Jean-Pierre ; Malghem, Jacques ; Noël, Henri ; Nagant de Deuxchaisnes, C. Antacid-induced osteomalacia.. In: Clinical rheumatology, Vol. 15, no. 1, p. 75-80 (1996)
Permanent URL http://hdl.handle.net/2078.1/26371
  1. Devogelaer, J.P., Le Thi, C., Depresseux, G., Nagant de Deuxchaisnes, C. A study of the accuracy of three DPA, and one dual-energy X-ray bone densitometers. Calcif Tissue Int 1990, 46, 140.
  2. Johnson, W.J., O'Brien, P.C. Effectiveness of intestinal phosphate binders in patients maintained by hemodialysis. Nephron 1978, 21, 123–130.
  3. Pronove, P., Bell, N.H., Bartter, F.C. Production of hypercalciuria by phosphorus deprivation on a low calcium intake: A new clinical test for hyperparathyroidism. Metabolism 1961, 10, 364–371.
  4. Balasa, RW, Murray RL, Kondelis NP, Bischel MD. Phosphate-binding properties and electrolyte content of aluminum hydroxide antacids. Nephron 1987; 45: 16–21.
  5. Lotz, M., Zisman, E., Bartter, F.C. Evidence for a phosphorus-depletion syndrome in man. N Engl J Med 1968, 278, 409–415.
  6. Spencer, H., Kramer, L., Norris, C., Osis, D. Effect of small doses of aluminum-containing antacids on calcium and phosphorus metabolism. Am J Clin Nutr 1982, 36, 32–40.
  7. Bloom Walter L., Osteomalacia with Pseudofractures Caused by the Ingestion of Aluminum Hydroxide, 10.1001/jama.1960.63030100015026a
  8. Lotz, M., Ney, R., Bartter, F.C., Smith, H. Osteomalacia and debility resulting from phosphorus depletion? Trans Assoc Am Physicians 1964, 77, 281–293.
  9. Ludwig, G.D., Kyle, G.C., De Blanco, M. “Tertiary” hyperparathyroidism induced by osteomalacia resulting from phosphorus depletion. Am J Med 1967, 43, 136–140.
  10. Baker, L.R.I., Ackrill, P., Cattell, W.R., Stamp, T.C.B., Watson, L. Iatrogenic osteomalacia and myopathy due to phosphate depletion. Br Med J 1974, 3, 150–152.
  11. Dent, C.E., Winter, C.S. Osteomalacia due to phosphate depletion from excessive aluminium hydroxide ingestion. Br Med J 1974, 1, 551–552.
  12. Cooke, N., Teitelbaum, S., Avioli, L.V. Antacid-induced osteomalacia and nephrolithiasis. Arch Int Med 1978, 138, 1007–1009.
  13. Insogna, K.L., Bordley, D.R., Caro, J.F., Lockwood, D.H. Osteomalacia and weakness from excessive antacid ingestion. JAMA 1980, 244, 2544–2546.
  14. Carmichael, K.A., Fallon, M.D., Dalinka, M., Kaplan, F.S., Axel, L., Haddad, J.G. Osteomalacia and osteitis fibrosa in a man ingesting aluminum hydroxide antacid. Am J Med 1984, 76, 1137–1143.
  15. Godsall, J.W., Baron, R., Insogna, K.L. Vitamin D metabolism and bone histomorphometry in a patient with antacid-induced osteomalacia. Am J Med 1984, 77, 747–750.
  16. Saadeh G., Bauer T., Licata A., Sheeler L., Antacid-induced osteomalacia, 10.3949/ccjm.54.3.214
  17. Levy Y, Bansal M, Zackson DA, Lane J, Shike M, Phosphate depletion syndrome: case report with bone and muscle histology findings and review of the literature, 10.1177/0148607188012003313
  18. Neumann L, Jensen BG. Osteomalacia from Al and Mg antacids. Report of a case of bilateral hip fracture. Acta Orthop Scand 1989, 60, 361–362.
  19. Chines, A., Pacifici, R. Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. Calcif Tissue Int 1990, 47, 291–295.
  20. Kassem, M., Eriksen, E.F., Melsen, F., Moselkilde, L. Antacid-induced osteomalacia: a case report with a histomorphometric analysis. J Int Med 1991, 229, 275–279.
  21. Foldes, J., Balena, R., Ho, A., Parfitt, A.M., Kleerekoper, M. Hypophosphatemic rickets with hypocalciuria following long-term treatment with aluminum-containing antacid. Bone 1991, 12, 67–71.
  22. Nesbitt, T., Davidai, G.A., Brazy, P.C., Drezner, M.K. Clinical disorders of phosphorus and vitamin D metabolism. In: Clinical Disorders of Bone and Mineral Metabolism. Eds.: Kleerekoper, M., Krane, S. Mary Ann Liebert, Inc. New York 1989, pp. 469–474.
  23. Morris, R.C., Halloran, B.P., Portale, A.A. The role of phosphorus in modulating vitamin D metabolism in health and disease. In: Clinical Disorders of Bone and Mineral Metabolism. Eds: Kleerekoper M, Krane S, Mary Ann Liebert, Inc. New York 1989, pp. 455–467.
  24. Maierhofer, W.S., Gray, R.W., Lemann, J. Phosphate deprivation increases serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int 1984, 25, 571–575.
  25. Christensson, T., Hellström, K., Wengle, B., Alveryd, A., Wikland, B. Prevalence of hypercalcaemia in a health screening in Stockholm. Acta Med Scand 1976, 200, 131–137.
  26. Ott, S.M., Maloney, N.A., Coburn, J.W., Alfrey, A.C., Sherrard, D.J. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med 1982, 307, 709–713.
  27. Klein, G.L., Alfrey, A.C., Miller, N.L., Sherrard, D.J., Hazlet, T.K., Ament, M.E., Coburn, J.W. Aluminum loading during total parenteral nutrition. Am J Clin Nutr 1982, 35, 1425–1429.
  28. WILLIAMS JAMES W., Biliary Excretion of Aluminum in Aluminum Osteodystrophy with Liver Disease, 10.7326/0003-4819-104-6-782
  29. Nagant de Deuxchaisnes, C., Rombouts-Lindemans, C., Huaux, J.P., Withofs, H., Meersseman, F. Healing of vitamin D-deficient osteomalacia by the administration of 1,25-(OH)2D3, In: Molecular Endocrinology. Eds.: MacIntyre, I., Szelke, M. Amsterdam, 1979, Elsevier/North-Holland Biomedical Press pp. 375–404.